Seminars in Hematology
Volume 45 , Pages S25-S30 , April 2008

Monitoring Inhibitor Patients With the Right Assays

  • Trevor W. Barrowcliffe

      Affiliations

    • Corresponding Author InformationAddress correspondence to Trevor W. Barrowcliffe, MA, PhD, 3 Boulby Bank, Whitby, Y022 4AN, UK.

References 

  1. DiMichele D. Inhibitors to factor VIII—Epidemiology and treatment. In:  Lee CA,  Berntorp E,  Hoots WK editor. Textbook of Haemophilia. Oxford, UK: Blackwell; 2005;p. 64–70
  2. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:612
  3. Austen DE, Lechner K, Rizza CR, Rhymes IL. A comparison of the Bethesda and New Oxford methods of factor VIII antibody assay. Thromb Haemost. 1982;47:72–75
  4. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: Improved specificity and reliability. Thromb Haemost. 1995;73:247–251
  5. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Thromb Haemost. 1998;79:872–875
  6. Verbruggen B, Meijer P. Performance of Bethesda assay and Nijmegen variant in external quality assessment (ECAT) of factor VIII inhibitor assays. J Thromb Haemost. 2007;5(suppl 2):O-T-093
  7. Raut S: A collaborative study of factor VIII inhibitors. Potters Bar, Hertfordshire, UK, National Institute for Biological Standards and Control, unpublished report, 2005
  8. Littlewood JD, Bevan SA, Kemball-Cook G, Evans RJ, Barrowcliffe TW. Variable inactivation of human factor VIII from different sources by human factor VIII inhibitors. Br J Haematol. 1991;77:535–538
  9. Gensana M, Altisent C, Aznar JA, Casaña P, Hernández F, Jorquera JI, et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia. 2001;7:369–374
  10. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993;81:734–744
  11. Johannessen M, Nielsen G, Nordfang O. Comparison of the factor VII:C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven). Blood Coagul Fibrinolysis. 2000;11(suppl 1):S159–S164
  12. Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost. 2001;86:954–958
  13. Cid AR, Lorenzo JI, Haya S, Montoro JM, Casaña P, Aznar JA. A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment. Haemophilia. 2001;7:39–41
  14. Goudemand J, Caron C, Dreyfus M, Sie P Haemostasis Standardization Group of the Groupe d'Etude Hémostase et Thrombose. Standardization of factor VII/activated factor VII measurement in plasma of patients treated with recombinant factor activated VII. Blood Coagul Fibrinolysis. 2003;14:505–511
  15. Hemker HC. The mode of action of heparin in plasma. In:  Verstraete M,  Vermylen J,  Lijnen R,  Arnout J editor. Thrombosis and Haemostasis. Leuven, Belgium: Leuven University Press; 1987;p. 17–36
  16. Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost. 1993;70:617–624
  17. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4–15
  18. McIntosh JH. Studies of the thrombin generation test in haemophilia. 2003;PhD Thesis, University of London
  19. MacFarlane RG, Biggs R. A thrombin generation test; the application in haemophilia and thrombocytopenia. J Clin Pathol. 1953;6:3–8
  20. Barrowcliffe TW, Kemball-Cook G, Gray E. Binding to phospholipid protects factor VIII from inactivation by human antibodies. J Lab Clin Med. 1983;101:34–43
  21. McIntosh JH, Owens D, Lee CA, Raut S, Barrowcliffe TW. A modified thrombin generation test for the measurement of factor VIII concentrates. J Thromb Haemost. 2003;1:1005–1011
  22. Livnat T, Zivelin A, Martinowitz U, Salomon O, Seligsohn U. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. J Thromb Haemost. 2006;4:192–200
  23. Dargaud Y, Lienhart A, Negrier C. Monitoring of recombinant FVIIa by thrombin generation test. J Thromb Haemost. 2007;5:P-M-176;(suppl 2, abstr)
  24. Eichinger S, Lubsczyk B, Gleiss A, Quehenberger P, Kyrle PA. Effects of recombinant factor VIIa (NovoSeven) on restoring thrombin generation in patients with haemophilia A and antibodies to factor VIII. J Thromb Haemost. 2007;5(suppl 2):P-S-176
  25. van Veen JJ, Gatt A, Bowyer A, Cooper PC, Kitchen S, Makris M. Thrombin generation to monitor inhibitor bypass agents requires low concentrations of tissue factor (TF). J Thromb Haemost. 2007;5(suppl 2):P-W-152
  26. Windyga J, Varadi K, Baran B, Keil B, Turecek P. The effect of APCC and PCC on the generation of thrombin in haemophilia A patients with FVIII inhibitor: A cross-over pharmacokinetic study. J Thromb Haemost. 2007;5(suppl 2):P-W-118
  27. Kenet G, Stenmo CB, Blemings A, Wegert W, Goudemand J, Krause M, et al. Intra-subject variability of thromboelastographic parameters following rFVIIa in vivo administration in haemophilia patients: a multi-centre, randomized trial. J Thromb Haemost. 2007;5(suppl 2):P-T-164
  28. Viuff D, Ezban M, Lind V, Dillow A, Raymer R, Merricks E, et al. Effect of rFVIIa and NN1731 (rFVIIa analogue) on thromboelastography (TEG) in whole blood obtained from haemophilia A dogs. J Thromb Haemost. 2007;5(suppl 2):P-W-113
  29. Larsen LF, Ezban M, Hedner U, Nicolaisen EM, Tengborn L. A whole blood clotting method measuring ex vivo effects of rFVIIa and FVIII in haemophilia blood. J Thromb Haemost. 2007;5(suppl 2):P-M-139
  30. Elm T, Ezban M, Tranholm M. Whole blood clotting time (WBCT) compared to in vivo dose response of rFVIIa in FVIII-KO mice. J Thromb Haemost. 2007;5(suppl 2):P-S-178
  31. Bordet J, Plantier J, Ovanesov M, Volpert V, Ataullakhanov F, Negrier C. Wall clot growth in plasma: effect of high doses of recombinant FVIIa. J Thromb Haemost. 2007;5(suppl 2):P-M-170

 STATEMENT OF CONFLICT OF INTEREST: Trevor Barrowcliffe has worked as a consultant for Novo Nordisk, on topics unrelated to the subject of this article.

PII: S0037-1963(08)00042-5

doi: 10.1053/j.seminhematol.2008.03.002

Seminars in Hematology
Volume 45 , Pages S25-S30 , April 2008

Article Tools

* Image Usage & Resolution